Trial Profile
A Phase I, Double-blind, Placebo Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects in Healthy Male and Female Japanese Subjects After Single and Multiple Doses (Bid) of AZD1722
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Dec 2014
Price :
$35
*
At a glance
- Drugs Tenapanor (Primary)
- Indications Heart failure; Hyperphosphataemia; Irritable bowel syndrome; Kidney disorders
- Focus Adverse reactions
- Sponsors Ardelyx
- 23 Oct 2014 Results presented at American Society of Nephrology (ASN) Kidney Week 2014, according to an Ardelyx media release.
- 02 Jul 2014 New trial record